The role of ventral striatal cAMP signaling in stress-induced behaviors

Nature Neuroscience

Volumn 18, Issue 8, 2015, Pages 1094-1100

  Plattner, Florian ^a   Hayashi, Kanehiro ^a,k,l   Hernández, Adan ^a   Benavides, David R ^a,k   Tassin, Tara C ^a   Tan, Chunfeng ^a   Day, Jonathan ^b   Fina, Maggy W ^c   Yuen, Eunice Y ^d   Yan, Zhen ^d   Goldberg, Matthew S ^a,c   Nairn, Angus C ^e,f   Greengard, Paul ^f   Nestler, Eric J ^g   Taussig, Ronald ^c   Nishi, Akinori ^h   Houslay, Miles D ⁱ   Bibb, James A ^a,c,j  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ROCKEFELLER UNIVERSITY   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIN DEPENDENT KINASE 5; DOPAMINE 1 RECEPTOR; PHOSPHODIESTERASE IV; CDK5 PROTEIN, MOUSE; CYCLIC AMP DEPENDENT PROTEIN KINASE;

ACUTE STRESS; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; FOREBRAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; STRESS; STRESS INDUCED BEHAVIOR; VENTRAL STRIATUM; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; KNOCKOUT MOUSE; MENTAL STRESS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLIN-DEPENDENT KINASE 5; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; VENTRAL STRIATUM;

EID: 84938417105     PISSN: 10976256     EISSN: 15461726     Source Type: Journal    
DOI: 10.1038/nn.4066     Document Type: Article

References (62)

1. Conti, M. & Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
2. Houslay, M.D. Underpinning compartmentalized cAMP signaling through targeted cAMP breakdown. Trends Biochem. Sci. 35, 91-100 (2010).
3. Sette, C. & Conti, M. Phosphorylation and activation of a cAMP-specifc phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271, 16526-16534 (1996).
4. MacKenzie, S.J. et al. Long PDE4 cAMP-specifc phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br. J. Pharmacol. 136, 421-433 (2002).
5. Bibb, J.A. et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402, 669-671 (1999).
6. Dhavan, R. & Tsai, L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol. 2, 749-759 (2001).
7. Angelo, M., Plattner, F. & Giese, K.P. Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J. Neurochem. 99, 353-370 (2006).
8. Plattner, F. et al. Memory enhancement by targeting Cdk5 regulation of NR2B. Neuron 81, 1070-1083 (2014).
9. Meyer, D.A. et al. Ischemic stroke injury is mediated by aberrant Cdk5. J. Neurosci. 34, 8259-8267 (2014).
10. Barnett, D.G. & Bibb, J.A. The role of Cdk5 in cognition and neuropsychiatric and neurological pathology. Brain Res. Bull. 85, 9-13 (2011).
11. Su, S.C. & Tsai, L.H. Cyclin-dependent kinases in brain development and disease. Annu. Rev. Cell Dev. Biol. 27, 465-491 (2011).
12. Fischer, A., Sananbenesi, F., Schrick, C., Spiess, J. & Radulovic, J. Cyclin-dependent kinase 5 is required for associative learning. J. Neurosci. 22, 3700-3707 (2002).
13. Bignante, E.A. et al. Involvement of septal Cdk5 in the emergence of excessive anxiety induced by stress. Eur. Neuropsychopharmacol. 18, 578-588 (2008).
14. Bignante, E.A., Paglini, G. & Molina, V.A. Previous stress exposure enhances both anxiety-like behavior and p35 levels in the basolateral amygdala complex: modulation by midazolam. Eur. Neuropsychopharmacol. 20, 388-397 (2010).
15. Zhu, W.L. et al. Increased Cdk5/p35 activity in the dentate gyrus mediates depressive-like behavior in rats. Int. J. Neuropsychopharmacol. 15, 795-809 (2012).
16. Zhong, P. et al. Cyclin-dependent kinase 5 in the ventral tegmental area regulates depression-related behaviors. J. Neurosci. 34, 6352-6366 (2014).
17. Carlson, J.N., Fitzgerald, L.W., Keller, R.W. Jr. & Glick, S.D. Side and region dependent changes in dopamine activation with various durations of restraint stress. Brain Res. 550, 313-318 (1991).
18. Chrapusta, S.J., Wyatt, R.J. & Masserano, J.M. Effects of single and repeated footshock on dopamine release and metabolism in the brains of Fischer rats. J. Neurochem. 68, 2024-2031 (1997).
19. Tye, K.M. et al. Dopamine neurons modulate neural encoding and expression of depression-related behavior. Nature 493, 537-541 (2013).
20. Chaudhury, D. et al. Rapid regulation of depression-related behaviors by control of midbrain dopamine neurons. Nature 493, 532-536 (2013).
21. Hawasli, A.H. et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci. 10, 880-886 (2007).
22. Weber, P., Metzger, D. & Chambon, P. Temporally controlled targeted somatic mutagenesis in the mouse brain. Eur. J. Neurosci. 14, 1777-1783 (2001).
23. Nestler, E.J. & Hyman, S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161-1169 (2010).
24. Schlaepfer, T.E. et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33, 368-377 (2008).
25. Nestler, E.J. & Carlezon, W.A. Jr. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59, 1151-1159 (2006).
26. Mungenast, A.E. & Tsai, L.H. Cognitive function in health and disease: the role of epigenetic mechanisms. Neurodegener. Dis. 10, 191-194 (2012).
27. Song, G.G., Kim, J.H. & Lee, Y.H. Genome-wide pathway analysis in major depressive disorder. J. Mol. Neurosci. 51, 428-436 (2013).
28. Hek, K. et al. A genome-wide association study of depressive symptoms. Biol. Psychiatry 73, 667-678 (2013).
29. Dwivedi, Y. & Pandey, G.N. Adenylyl cyclase-cyclicAMP signaling in mood disorders: role of the crucial phosphorylating enzyme protein kinase A. Neuropsychiatr. Dis. Treat. 4, 161-176 (2008).
30. Duman, R.S. & Voleti, B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 35, 47-56 (2012).
31. Fujita, M. et al. Downregulation of brain phosphodiesterase type IV measured with (11)C-(R)-rolipram positron emission tomography in major depressive disorder. Biol. Psychiatry 72, 548-554 (2012).
32. O'Donnell, J.M. & Xu, Y. Evidence for global reduction in brain cyclic adenosine monophosphate signaling in depression. Biol. Psychiatry 72, 524-525 (2012).
33. Halene, T.B. & Siegel, S.J. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia? Drug Discov. Today 12, 870-878 (2007).
34. Kleppisch, T. Phosphodiesterases in the central nervous system. Handb. Exp. Pharmacol. 191, 71-92 (2009).
35. Zeller, E., Stief, H.J. & Pfug, B. Sastre-y-Hernandez, M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 17, 188-190 (1984).
36. Zhang, H.T. et al. Antidepressant-like profle and reduced sensitivity to rolipram in mice defcient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27, 587-595 (2002).
37. O'Donnell, J.M. & Zhang, H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 25, 158-163 (2004).
38. Houslay, M.D., Schafer, P. & Zhang, K.Y. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10, 1503-1519 (2005).
39. Burgin, A.B. et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat. Biotechnol. 28, 63-70 (2010).
40. Nestler, E.J. et al. Neurobiology of depression. Neuron 34, 13-25 (2002).
41. Mayberg, H.S. et al. Reciprocal limbic-cortical function and negative mood: converging PET fndings in depression and normal sadness. Am. J. Psychiatry 156, 675-682 (1999).
42. Schmidt, E.F. et al. Identifcation of the cortical neurons that mediate antidepressant responses. Cell 149, 1152-1163 (2012).
43. Warner-Schmidt, J.L. et al. Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc. Natl. Acad. Sci. USA 109, 11360-11365 (2012).
44. Bibb, J.A. et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 410, 376-380 (2001).
45. Benavides, D.R. et al. Cdk5 modulates cocaine reward, motivation, and striatal neuron excitability. J. Neurosci. 27, 12967-12976 (2007).
46. Kim, S.H. & Ryan, T.A. CDK5 serves as a major control point in neurotransmitter release. Neuron 67, 797-809 (2010).
47. Tan, T.C. et al. Cdk5 is essential for synaptic vesicle endocytosis. Nat. Cell Biol. 5, 701-710 (2003).
48. Johansson, E.M., Reyes-Irisarri, E. & Mengod, G. Comparison of cAMP-specifc phosphodiesterase mRNAs distribution in mouse and rat brain. Neurosci. Lett. 525, 1-6 (2012).
49. Mathews, D.C., Henter, I.D. & Zarate, C.A. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 72, 1313-1333 (2012).
50. Castagne, V., Moser, P., Roux, S. & Porsolt, R.D. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr. Protoc. Neurosci. 8.8, 10A (2011).
51. Golden, S.A., Covington, H.E. III., Berton, O. & Russo, S.J. A standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 6, 1183-1191 (2011).
52. Willner, P., Towell, A., Sampson, D., Sophokleous, S. & Muscat, R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl.) 93, 358-364 (1987).
53. Yuen, E.Y. et al. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73, 962-977 (2012).
54. Nishi, A., Snyder, G.L. & Greengard, P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147-8155 (1997).
55. Nishi, A. et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J. Neurosci. 28, 10460-10471 (2008).
56. Frank-Cannon, T.C. et al. Parkin defciency increases vulnerability to infammation-related nigral degeneration. J. Neurosci. 28, 10825-10834 (2008).
57. Marchmont, R.J. & Houslay, M.D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem. J. 187, 381-392 (1980).
58. Lobban, M., Shakur, Y., Beattie, J. & Houslay, M.D. Identifcation of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions. Biochem. J. 304, 399-406 (1994).
59. Jiang, L.I. et al. Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J. Biol. Chem. 282, 10576-10584 (2007).
60. Murdoch, H. et al. Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J. Neurosci. 27, 9513-9524 (2007).
61. Zhao, Y., Zhang, W. & White, M.A. Capillary high-performance liquid chromatography/mass spectrometric analysis of proteins from affnity-purifed plasma membrane. Anal. Chem. 75, 3751-3757 (2003).
62. Czernik, A.J., Mathers, J. & Mische, S.M. Phosphorylation state-specifc antibodies. in Regulatory Protein Modifcation: Techniques and Protocols Neuromethods, Vol. 30 (ed. H.C. Hemmings, Jr.) 219-250 (Humana Press, 1997).